Trials / Unknown
UnknownNCT03383952
A Clinical Study of CD19 Targeted CAR-T for Patients With CD19+ Lymphoma and Leukemia
A Phase I Trial of CD19 Targeted ICAR19 T Cells in Patients With CD19+ Leukemia and Lymphoma.
- Status
- Unknown
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 20 (estimated)
- Sponsor
- Immune Cell, Inc. · Industry
- Sex
- All
- Age
- 2 Years – 80 Years
- Healthy volunteers
- Not accepted
Summary
Immunotherapy offers an extremely precise approach with the potential to eliminate cancer cells specifically. The newly designed CD19 targeted ICAR19 T cells can specifically kill CD19+ tumor cells. ICAR19 CART used the second generation of CART designation. In this study, the participants will receive several doses of autologous ICAR19 T cells and the investigators will determine the safety and therapeutic effects of these cells.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | ICAR19 CAR-T cells | T cells were isolated from peripheral blood from patients enrolled. T cells were transduced with lentivirus bearing anti-CD19 antibody scFV and the activation signals of second generation CART designation. The CART cells were infused into the patients by IV with an escalating dosage. |
Timeline
- Start date
- 2017-03-01
- Primary completion
- 2020-12-31
- Completion
- 2025-12-31
- First posted
- 2017-12-27
- Last updated
- 2017-12-27
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT03383952. Inclusion in this directory is not an endorsement.